- Home
- NGNE vs NRC Comparison
NGNE vs NRC Comparison
Compare NGNE & NRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- NRC
- Stock Information
- Founded
- NGNE 2003
- NRC 1981
- Country
- NGNE United States
- NRC United States
- Employees
- NGNE N/A
- NRC N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- NRC Biotechnology: Commercial Physical & Biological Resarch
- Sector
- NGNE Health Care
- NRC Health Care
- Exchange
- NGNE Nasdaq
- NRC Nasdaq
- Market Cap
- NGNE 325.3M
- NRC 354.5M
- IPO Year
- NGNE N/A
- NRC N/A
- Fundamental
- Price
- NGNE $18.48
- NRC $14.65
- Analyst Decision
- NGNE Strong Buy
- NRC
- Analyst Count
- NGNE 7
- NRC 0
- Target Price
- NGNE $41.86
- NRC N/A
- AVG Volume (30 Days)
- NGNE 110.1K
- NRC 101.8K
- Earning Date
- NGNE 08-11-2025
- NRC 10-24-2025
- Dividend Yield
- NGNE N/A
- NRC 3.27%
- EPS Growth
- NGNE N/A
- NRC N/A
- EPS
- NGNE N/A
- NRC 0.77
- Revenue
- NGNE N/A
- NRC $140,314,000.00
- Revenue This Year
- NGNE N/A
- NRC N/A
- Revenue Next Year
- NGNE N/A
- NRC N/A
- P/E Ratio
- NGNE N/A
- NRC $19.08
- Revenue Growth
- NGNE N/A
- NRC N/A
- 52 Week Low
- NGNE $6.88
- NRC $9.76
- 52 Week High
- NGNE $74.49
- NRC $22.99
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- NRC 47.80
- Support Level
- NGNE $19.59
- NRC $14.45
- Resistance Level
- NGNE $20.46
- NRC $15.60
- Average True Range (ATR)
- NGNE 1.23
- NRC 0.64
- MACD
- NGNE -0.20
- NRC -0.03
- Stochastic Oscillator
- NGNE 13.37
- NRC 17.05
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About NRC National Research Corporation (Delaware)
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.